ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California. Show more
Location: 11682 El Camino Real, San Diego, CA, 92130, United States | Website: https://ars-pharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.075B
52 Wk Range
$10.00 - $18.90
Previous Close
$10.88
Open
$10.95
Volume
3,835,357
Day Range
$10.33 - $11.03
Enterprise Value
836.8M
Cash
240.1M
Avg Qtr Burn
-13.2M
Insider Ownership
16.83%
Institutional Own.
86.21%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I) | Approved Quarterly sales | |
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I) | Approved Quarterly sales | |
neffy® (epinephrine nasal spray) Details Acute flares in patients with chronic spontaneous urticaria | Phase 2b Data readout | |
SBT6050 (TLR8 Agonist) Details Cancer, Breast cancer | Failed Discontinued |